Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| 1-(2-chloro-4-((6-cyano-7-methoxyquinolin-4-yl)oxy)phenyl)-3-cyclopropylurea | One of the impurities of Lenvatinib. Lenvatinib is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/&beta. Synonyms: 6-Cyano Lenvatinib; N-[2-Chloro-4-[(6-cyano-7-methoxy-4-quinolinyl)oxy]phenyl]-N'-cyclopropyl Urea; Lenvatinib Impurity 11. CAS No. 1882873-21-3. Molecular formula: C21H17ClN4O3. Mole weight: 408.84. |  |
| (1α, 3α, 5α)-3, 5-dihydroxy-cyclohexanecarboxylic Acid Methyl Ester | (1α, 3α, 5α)-3, 5-dihydroxy-cyclohexanecarboxylic Acid Methyl Ester can be used as a starting material to synthesize pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases. Group: Biochemicals. Grades: Highly Purified. CAS No. 156526-48-6. Pack Sizes: 500mg, 5g. Molecular Formula: C8H14O4, Molecular Weight: 174.19. US Biological Life Sciences. |  Worldwide |
| 2,4-Dichloro-3-aminophenol Hydrochloride | 2,4-Dichloro-3-aminophenol Hydrochloride is a useful reagent in the study fo aryl-pyrimidinyl ureas preparation as potential FGFR tyrosine kinase inhibitors and antitumor agents. Group: Biochemicals. Grades: Highly Purified. CAS No. 61693-43-4. Pack Sizes: 100mg, 250mg. Molecular Formula: C6H5Cl2NO; HCl, Molecular Weight: 178.023646. US Biological Life Sciences. | Worldwide |
| 3-Chloro-4-(4-methyl-1-piperazinyl)benzoic Acid | 3-Chloro-4-(4-methyl-1-piperazinyl)benzoic acid acts as a reagent in the preparation of 1H-pyrazolo[3,4-b]pyridines as fibroblast growth factor receptor inhibitors (FGFRs). Fibroblast growth factor receptors are important targets for cancer therapy. Group: Biochemicals. Grades: Highly Purified. CAS No. 1197193-33-1. Pack Sizes: 25mg, 50mg. Molecular Formula: C12H15ClN2O2, Molecular Weight: 254.71. US Biological Life Sciences. | Worldwide |
| 4-((2-chloro-4-hydroxyphenyl)amino)-7-methoxyquinoline-6-carboxamide | One of the impurities of Lenvatinib. Lenvatinib is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/&beta. Synonyms: Lenvatinib Impurity 02; 6-Quinolinecarboxamide, 4-[(2-chloro-4-hydroxyphenyl)amino]-7-methoxy-. CAS No. 2380197-89-5. Molecular formula: C17H14ClN3O3. Mole weight: 343.76. | |
| 4-(3-chloro-4-(3,3-dimethylureido)phenoxy)-7-methoxyquinoline-6-carboxamide | One of the impurities of Lenvatinib. Lenvatinib is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/&beta. Synonyms: 6-Quinolinecarboxamide, 4-[3-chloro-4-[[ (dimethylamino) carbonyl]amino]phenoxy]-7-methoxy-; Lenvatinib Impurity 07. CAS No. 2143930-76-9. Molecular formula: C20H19ClN4O4. Mole weight: 414.84. | |
| 4-(3-chloro-4-(3-methylureido)phenoxy)-7-methoxyquinoline-6-carboxamide | One of the impurities of Lenvatinib. Lenvatinib is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/&beta. Synonyms: 6-Quinolinecarboxamide, 4-[3-chloro-4-[[ (methylamino)carbonyl]amino]phenoxy]-7-methoxy-; Lenvatinib Impurity 06. CAS No. 417719-45-0. Molecular formula: C19H17ClN4O4. Mole weight: 400.82. | |
| 4-(4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide | One of the impurities of Lenvatinib. Lenvatinib is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/&beta. Synonyms: 1-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)phenyl)-3-cyclopropylurea; Lenvatinib Impurity 03. CAS No. 417714-14-8. Molecular formula: C21H20N4O4. Mole weight: 392.41. | |
| 4-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)amino)-3-chlorophenoxy)-7-methoxyquinoline-6-carboxamide | One of the impurities of Lenvatinib. Lenvatinib is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/&beta. Synonyms: Lenvatinib Impurity 01. CAS No. 2380197-90-8. Molecular formula: C28H22ClN5O5. Mole weight: 543.96. | |
| 4,4'-(((carbonylbis(azanediyl))bis(3-chloro-4,1-phenylene))bis(oxy))bis(7-methoxyquinoline-6-carboxamide) | One of the impurities of Lenvatinib. Lenvatinib is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/&beta. Synonyms: 1,3-bis(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)urea; 4,4'-[Carbonylbis[imino(3-chloro-4,1-phenylene)oxy]]bis[7-methoxy-6-quinolinecarboxamide]; Lenvatinib Impurity 04. CAS No. 2143930-75-8. Molecular formula: C35H26Cl2N6O7. Mole weight: 713.52. | |
| 6-Amino-2,3-dimethyl-2H-indazole Hydrochloride | An impurity of Pazopanib, which is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms. Synonyms: 2H-Indazol-6-amine, 2,3-dimethyl-, hydrochloride (1:1); 2H-Indazol-6-amine, 2,3-dimethyl-, monohydrochloride; 2,3-Dimethyl-2H-indazol-6-amine hydrochloride; 2,3-Dimethyl-6-amino-2H-indazole hydrochloride. Grades: ≥95%. CAS No. 635702-60-2. Molecular formula: C9H12ClN3. Mole weight: 197.66. | |
| ACTB-1003 | ACTB-1003 is an oral kinase inhibitor with multiple modes of action, targeting cancer mutations via FGFR inhibition FGFR1, angiogenesis through inhibition of VEGFR2, Tie-2, and induces apoptosis likely by targeting RSK and p70S6K. It is highly active with dose-dependent tumor growth inhibition in cell lines with FGFR genetic alterations - OPM2 human multiple myeloma and the murine leukemia Ba/F3-TEL-FGFR1. Synonyms: ACTB1003; ACTB 1003; ACTB-1003. Grades: >98%. CAS No. 939805-30-8. Molecular formula: C27H26F5N7O3. Mole weight: 591.53. | |
| Alofanib | Alofanib, also known as RPT835, is a potent and selective allosteric inhibitor of FGFR2 with potential anticancer activity. Alofanib blocks the extracellular part of the receptor and prevents its binding with the ligand. Alofanib suppressed proliferation of endothelial cells, their migration activity, and ability to form vessellike structures in vitro and significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo. RPT835 potently inhibited growth of KATO III gastric cancer cells expressing FGFR2, with GI50 value of 10 nmol/L. Uses: Designed for use in research and industrial production. Additional or Alternative Names: RPT835; RPT-835; RPT 835; Alofanib. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1612888-66-0. Molecular formula: C19H15N3O6S. Mole weight: 413.4. Purity: >98%. IUPACName: 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid. Canonical SMILES: O=[N+](C1=CC(C)=C(C2=CC=CN=C2)C=C1NS(=O)(C3=CC(C(O)=O)=CC=C3)=O)[O-]. Product ID: ACM1612888660. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Alofanib | Alofanib, also known as RPT835, is a potent and selective allosteric inhibitor of FGFR2 with potential anticancer activity. Alofanib blocks the extracellular part of the receptor and prevents its binding with the ligand. Synonyms: RPT835; RPT-835; RPT 835; Alofanib. Grades: 95%. CAS No. 1612888-66-0. Molecular formula: C19H15N3O6S. Mole weight: 413.404. | |
| Alofanib | Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 ( FGFR2 ). Anticancer and antiangiogenic activity [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: RPT835. CAS No. 1612888-66-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-17601. |  |
| Anlotinib Dihydrochloride | Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenic activities, which was designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, and Ret. Synonyms: 1- [ [ [4- [ (4-fluoro-2-methyl-1H-indol-5-yl) oxy] -6-methoxy-7-quinolinyl] oxy] methyl] cyclopropanamine Hydrochloride (1:2); AL3818 Dihydrochloride; Anlotinib 2HCl; AL3818 2HCl. CAS No. 1360460-82-7. Molecular formula: C23H22FN3O3.2ClH. Mole weight: 480.36. | |
| ARQ-087 | ARQ-087, also known as Derazantinib, is an oral fibroblast growth factor receptor (FGFR) inhibitor with antitumor property. FGFR plays a role in the regulation of key cellular behaviors including proliferation, cell differentiation and so on. FGFR dysregulation is considered as a driver in multiple cancers. ARQ 087 binds to FGFR and effectively inhibits the activation of FGFR thus can suppress tumorigenesis and tumor growth. Synonyms: ARQ 087; ARQ087; ARQ-087; Derazantinib; (6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine. Grades: ≥98%. CAS No. 1234356-69-4. Molecular formula: C29H29FN4O. Mole weight: 468.576. | |
| ASP5878 | ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4 , with IC 50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1453208-66-6. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19983. | |
| ATR Kinase Inhibitor II (3-Amino-6-(4-((1-(dimethylamino)propan-2-yl)sulfonyl)-phenyl)-N-phenylpyrazine-2-carboxamide) | A cell-permeable aminopyrazinyl-sulfone compound that acts as a potent, reversible and ATP-competitive inhibitor of ATR kinase (IC50 = 12nM; Ki=6nM) with excellent selectivity over ATM, DNA-PK (IC50 > 8uM) and in a 50-kinase panel (% inhibition at 2uM = 59, 57, 55, 52, 43 and 42 for AMPK, Lck, RIPK2, Ret, IKK-alpha and FGFR3, respectively). Shown to block pH2AX-Ser139 (IC50 = 420nM in hydroxyurea treated HT29 cells) and preferentially enhance cisplatin cytotoxicity against tumor cells over normal cells by ~7-fold at 620nM. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. | Worldwide |
| AZD-4547 | AZD4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. Synonyms: AZD-4547; AZD 4547; AZD4547; N-{3-[2-(3,5-Dimethoxyphenyl)ethyl]-1h-Pyrazol-5-Yl}-4-[(3r,5s)-3,5-Dimethylpiperazin-1-Yl]benzamide. Grades: 98%. CAS No. 1035270-39-3. Molecular formula: C26H33N5O3. Mole weight: 463.582. | |
| BAY 826 | BAY-826 is a selective and potent TIE-2 inhibitor with Kd of 1.6 nM and IC50 of 1.3 nM for autophosphorylation. BAY-826 is highly selective against other angiogenic kinases, such as VEGFR, FGFR, or PDGFR, and affects VEGF-stimulated proliferation of HUVEC. It displays in vivo efficacy in some murine glioma models. Synonyms: [3-Cyano-5- [ [ [2, 4-dimethyl-5- [6- (3-pyridinyl) -1H-imidazo [1, 2-b] pyrazol-1-yl] phenyl] amino] carbonyl] phenyl] pentafluorosulfur. Grades: ≥98% by HPLC. CAS No. 1448316-08-2. Molecular formula: C26H19F5N6OS. Mole weight: 558.53. | |
| Bemarituzumab | Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research [1]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1952272-74-0. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99010. | |
| BGJ-398 | BGJ398, also known as NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Synonyms: 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea; NVPBGJ398; NVPBGJ 398; NVPBGJ-398; BGJ398; BGJ-398; BG J398; Infigratinib. Grades: 0.98. CAS No. 872511-34-7. Molecular formula: C26H31Cl2N7O3. Mole weight: 560.48. | |
| BLU-554 | BLU-554 is a potent and selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) (IC50 = 5 nM), which is promisingly to be used for the treatment of hepatocellular carcinoma and cholangiocarcinoma. Synonyms: BLU-554; BLU 554; BLU554, Fisogatinib; SCHEMBL16668287; EX-A841; MFCD30496704; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]amino]oxan-4-yl]prop-2-enamide; BLU554. Grades: 99.08 %. CAS No. 1707289-21-1. Molecular formula: C24H24Cl2N4O4. Mole weight: 503.38. | |
| BLU9931 | BLU9931 is a potent and irreversible small-molecule inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway. BLU9931 is exquisitely selective for FGFR4 versus other FGFR family members and all other kinases. Synonyms: BLU9931; BLU-9931; BLU 9931. Grades: 98%. CAS No. 1538604-68-0. Molecular formula: C26H22Cl2N4O3. Mole weight: 509.38. | |
| BLU9931 | BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 3 nM and a Kd of 6 nM. BLU9931 has significant antitumor activity[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1538604-68-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg. Product ID: HY-12823. | |
| BMS-195270 | BMS-195270 is a robust and discriminating small molecule inhibitor, finding paramount application in the biomedical sector. Its remarkable efficacy against fibroblast growth factor receptor 4 (FGFR4) imparts exceptional potency, rendering it a formidable intervention modality for malignancies driven by FGFR4. Synonyms: 2-(5-chloro-2-hydroxyphenyl)-5-[2-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-one; BMS-195270; BMS 195270; BMS195270; UNII-20UM0T170J; CHEMBL13637; SCHEMBL5754043; 20UM0T170J. Grades: >98%. CAS No. 202822-23-9. Molecular formula: C15H9ClF3N3O2. Mole weight: 355.7. | |
| BO-264 | BO-264 is a highly potent and orally active transforming acidic coiled-coil 3 (TACC3) inhibitor with an IC50 of 188 nM and a Kd of 1.5 nM. BO-264 specifically blocks the function of FGFR3-TACC3 fusion protein. BO-264 induces spindle assembly checkpoint (SAC)-dependent mitotic arrest, DNA damage and apoptosis. BO-264 has broad-spectrum antitumor activity[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2408648-20-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-135960. | |
| Brivanib | Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC 50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BMS-540215. CAS No. 649735-46-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10337. | |
| Brivanib (alaninate) | Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC 50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BMS-582664. CAS No. 649735-63-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10336. | |
| CEP-11981 | CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ESK981; BOL 303213X. CAS No. 856691-93-5. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-16135. | |
| Cevidoplenib | Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk) , with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC 50 s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: SKI-O-703. CAS No. 1703788-21-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109082. | |
| CHIR-99021 | A potent and highly selective inhibitor of glycogen synthase kinase-3beta (GSK-3b) (IC50 = 6.7nM). CHIR99021 has been shown to allow for long-term expansion of murine embryonic stem cells in a chemically-defined medium in conjunction with MEK/MAPK inhibitor PD184352 and fibroblast growth factor receptor (FGFR) inhibitor SU5402. Group: Biochemicals. Alternative Names: 6-((2-((4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2- yl) pyrimidin-2-yl) amino) ethyl) amino) nicotinonitrile; CT99021; CHIR 911. Grades: Highly Purified. CAS No. 252917-06-9. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| Debio-1347 | Debio-1347, also known as FF284 and CH5183284, is an orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity. FGFR inhibitor debio 1347 binds to and inhibits FGFR-1, -2, and -3, which result in the inhibition of FGFR-mediated signal transduction pathways. This leads to the inhibition of both tumor cell proliferation and angiogenesis, and causes cell death in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, is essential for tumor cellular proliferation, differentiation and survival. Synonyms: Debio-1347; Debio 1347; Debio1347; CH5183284; CH 5183284; CH-5183284; FF-284; FF284; FF 284. CAS No. 1265229-25-1. Molecular formula: C20H16N6O. Mole weight: 356.389. | |
| Derazantinib | Derazantinib (ARQ-087) is an ATP competitive and orally active FGFR inhibitor ( IC 50 s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3 nM). Derazantinib inhibits FGFR phosphorylation. Derazantinib inhibits tumor growth in multiple xenograft models [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ARQ-087. CAS No. 1234356-69-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19981. | |
| Derazantinib dihydrochloride | Derazantinib is an oral fibroblast growth factor receptor (FGFR) inhibitor with antitumor property. FGFR plays a role in the regulation of key cellular behaviors including proliferation, cell differentiation and so on. FGFR dysregulation is considered as a driver in multiple cancers. Derazantinib binds to FGFR and effectively inhibits the activation of FGFR thus can suppress tumorigenesis and tumor growth. Synonyms: Derazantinib hydrochloride; ARQ-087 dihydrochloride; ARQ-087 hydrochloride; ARQ-087 2HCl; ARQ 087 2HCl. CAS No. 1821329-75-2. Molecular formula: C29H31Cl2FN4O. Mole weight: 541.49. | |
| Derazantinib Racemate | Derazantinib Racemate (ARQ-087 Racemate) is the racemate of Derazantinib. Derazantinib is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC 50 s of 4.5, 1.8, and 4.5 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ARQ-087 Racemate. CAS No. 2309668-44-6. Pack Sizes: 10 mM * 1 mL; 1 mg; 2 mg. Product ID: HY-19981A. | |
| Desamino Hydroxy Lenvatinib | One of the impurities of Lenvatinib. Lenvatinib is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/&beta. Synonyms: Lenvatinib Impurity F; 4- (3-chloro-4- ( ( (cyclopropylamino) carbonyl) amino) phenoxy) -7-methoxy-6-quinolinecarboxylic acid; Lenvatinib Impurity 08. CAS No. 417717-21-6. Molecular formula: C21H18ClN3O5. Mole weight: 427.84. | |
| Descyclopropyl Lenvatinib | One of the impurities of Lenvatinib. Lenvatinib is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/&beta. Synonyms: 4-(3-Chloro-4-ureidophenoxy)-7-methoxyquinoline-6-carboxamide; 6-Quinolinecarboxamide, 4-(4-((aminocarbonyl)amino)-3-chlorophenoxy)-7-methoxy-; Lenvatinib Impurity 05. CAS No. 417719-51-8. Molecular formula: C18H15ClN4O4. Mole weight: 386.79. | |
| Desmethyl Nintedanib | An impurity of Nintedanib, which is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/73 nM. Synonyms: Nintedanib Impurity G; 2, 3-Dihydro-3- [ [ [4- [ [ (4-methyl-1-piperazinyl) acetyl] amino] phenyl] amino] phenylmethylene] -2-oxo-methyl Ester-1H-indole-6-carboxylic Acid; (Z)-Methyl 3- ( ( (4- (2- (4-methylpiperazin-1-yl)acetamido)phenyl)amino) (phenyl)methylene)-2-oxoindoline-6-carboxylate. CAS No. 894783-61-0. Molecular formula: C30H31N5O4. Mole weight: 525.60. | |
| DGY-06-116 | DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2556836-50-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-136605. | |
| Dovitinib | Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC 50 s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3 , c-Kit , CSF-1R , FGFR1/FGFR3 , VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ , respectively. Dovitinib has potent antitumor activity [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CHIR-258; TKI258. CAS No. 405169-16-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50905. | |
| Dovitinib Dilactic Acid | Dovitinib is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Synonyms: Dovitinib Dilactic acid; TKI258 Dilactic acid; CHIR-258; CHIR 258; CHIR258; TKI258; TKI 258; TKI-258. Grades: >98%. CAS No. 852433-84-2. Molecular formula: C27H33FN6O7. Mole weight: 572.59. | |
| Dovitinib lactate | Dovitinib, also referred as CHIR-258 or TKI258, is a potent receptor tyrosine kinase inhibitor (TKI) that selectively targets VEGFR, PDGFR, FGFR, CSF1R, c-KIT, RET, TrKA, and FLT3, and additionally targets FGFR (IC50 = 5 nM). Synonyms: 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one;2-hydroxypropanoic acid; 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate; Dovitinib(lactate); 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxy; CTK8B6779. CAS No. 692737-80-7. Molecular formula: C24H27FN6O4. Mole weight: 482.51. | |
| Dovitinib lactate | Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC 50 s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3 , c-Kit , FGFR1/3 , VEGFR1/2/3 and PDGFRα/β , respectively [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CHIR-258 lactate; TKI-258 lactate. CAS No. 692737-80-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-10207. | |
| Dovitinib Lactate Hydrate | Dovitinib lactate hydrate is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Synonyms: TKI258 lactate hydrate; CHIR-258 lactate hydrate; 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate hydrate; Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone, hydrate (1:1:1). Grades: >98%. CAS No. 915769-50-5. Molecular formula: C24H29FN6O5. Mole weight: 500.52. | |
| E 3810 dihydrochloride | E 3810 dihydrochloride is a dual VEGFR/FGFR tyrosine kinase inhibitor. It suppresses the tumor angiogenesis and tumor cell proliferation via inhibiting VEGFR1, -2, and -3 and FGFR-1 and -2 kinases in the nanomolar range. Uses: Antitumor agent. Synonyms: E 3810 dihydrochloride; E3810 dihydrochloride; E-3810 dihydrochloride; Lucitanib dihydrochloride; 6-[7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl]oxy-N-methylnaphthalene-1-carboxamide dihydrochloride. Grades: 99%. CAS No. 2108875-91-6. Molecular formula: C26H25N3O4.2HCl. Mole weight: 516.42. | |
| E7090 | E7090 is an orally available, potent, and selective FGFR inhibitor with IC 50 s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4 , respectively [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1622204-21-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101466. | |
| E7090 succinate | E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC 50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1879965-80-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101466A. | |
| ENMD-2076 | ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer. Synonyms: ENMD-2076; ENMD 2076; ENMD2076. CAS No. 934353-76-1. Molecular formula: C21H25N7. Mole weight: 375.47. | |
| Erdafitinib | Erdafitinib, also known as JNJ-42756493, is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Synonyms: JNJ-42756493; JNJ 42756493; JNJ42756493; Erdafitinib. Grades: 98%. CAS No. 1346242-81-6. Molecular formula: C25H30N6O2. Mole weight: 446.55. | |
| Erdafitinib | Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC 50 s of 1.2, 2.5, 3.0 and 5.7 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: JNJ-42756493. CAS No. 1346242-81-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-18708. | |
| Fazpilodemab | Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klotho?. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD)[1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: BFKB8488A; RG-7992; RO-7040551. CAS No. 2517935-02-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99614. | |
| Ferulic acid | Ferulic acid is a novel fibroblast growth factor receptor 1 ( FGFR1 ) inhibitor with IC 50 s of 3.78 and 12.5 μM for FGFR1 and FGFR2 , respectively. Uses: Scientific research. Group: Natural products. Alternative Names: Coniferic acid. CAS No. 1135-24-6. Pack Sizes: 10 mM * 1 mL; 100 mg; 1 g; 5 g. Product ID: HY-N0060. | |
| Ferulic acid sodium | Ferulic acid sodium is a novel fibroblast growth factor receptor 1 ( FGFR1 ) inhibitor with IC 50 s of 3.78 and 12.5 μM for FGFR1 and FGFR2 , respectively. Uses: Scientific research. Group: Natural products. Alternative Names: Coniferic acid sodium. CAS No. 24276-84-4. Pack Sizes: 10 mM * 1 mL; 100 mg; 1 g; 5 g. Product ID: HY-N0060A. | |
| Fexagratinib | Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the FGFR family with IC50s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AZD4547; ADSK091. CAS No. 1035270-39-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-13330. | |
| FGF-401 | FGF-401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4) (IC50 = 1.9 nM) developed for the treatment of solid tumor. Synonyms: FGF401; FGF-401; FGF 401; roblitinib; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide. CAS No. 1708971-55-4. Molecular formula: C25H30N8O4. Mole weight: 506.56. | |
| FGFR2-IN-2 | FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2677709-81-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145231. | |
| FGFR4-IN-1 | FGFR4-IN-1 is a potent and selective FGFR4 inhibitor. FGFR4 may be a novel therapeutic target for gastric cancer. Uses: Designed for use in research and industrial production. Additional or Alternative Names: FGFR4-IN-1; FGFR4-IN1; FGFR4-IN 1. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1708971-72-5. Molecular formula: C24H27N7O5. Mole weight: 493.52. Purity: >98%. IUPACName: N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((3-oxomorpholino)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide. Canonical SMILES: O=C(N1CCCC2=CC(CN3C(COCC3)=O)=C(C=O)N=C12)NC4=NC=C(C#N)C(NCCOC)=C4. Product ID: ACM1708971725. Alfa Chemistry ISO 9001:2015 Certified. | |
| FGFR4-IN-1 | FGFR4-IN-1 is a potent and selective FGFR4 inhibitor with potential for the treatment of gastric cancer. Synonyms: N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((3-oxomorpholino)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; FGFR4-IN-1; FGFR4-IN1; FGFR4-IN 1. CAS No. 1708971-72-5. Molecular formula: C24H27N7O5. Mole weight: 493.52. | |
| FGFR-IN-1 | FGFR-IN-1 is a potent FGFR inhibitor with an IC 50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1513860-41-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145043. | |
| FIIN-1 | FIIN-1 is a potent, irreversible and selective FGFR inhibitor with IC50s of 9.2, 6.2, 11.9 and 189 nM against FGFR1/2/3/4, respectively. FIIN-1 binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8, 6.9, 5.4, 120 nM and 32, 120 nM, respectively. Synonyms: FGFR irreversible inhibitor-1; N-[3-[[3-(2,6-Dichloro-3,5-dimethoxyphenyl)-7-[[4-(diethylamino)butyl]amino]-3,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]methyl]phenyl]-2-propenamide; Fibroblast Growth Factor Receptor Irreversible Inhibitor 1; N-[3-[[3-(2,6-Dichloro-3,5-dimethoxyphenyl)-7-[[4-(diethylamino)butyl]amino]-3,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]methyl]phenyl]acrylamide. Grades: ≥95%. CAS No. 1256152-35-8. Molecular formula: C32H39Cl2N7O4. Mole weight: 656.60. | |
| FIIN-1 | FIIN-1 is a potent, irreversible, selective FGFR inhibitor. FIIN-1 binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: FGFR irreversible inhibitor-1. CAS No. 1256152-35-8. Pack Sizes: 2 mg; 5 mg; 10 mg. Product ID: HY-15813. | |
| FIIN-2 | FIIN-2 is an irreversible inhibitor of FGFR with an IC50 of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1633044-56-0. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-18602. | |
| FIIN-2 | FIIN-2 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor. FIIN-2 is the first inhibitor that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clinical FGFR inhibitors such as NVP-BGJ398 and AZD4547. Synonyms: FIIN2; FIIN 2; FIIN-2. Grades: 98%. CAS No. 1633044-56-0. Molecular formula: C35H38N8O4. Mole weight: 634.73. | |
| FIIN-3 | FIIN-3 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor. FIIN-3 is the first inhibitor that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clinical FGFR inhibitors such as NVP-BGJ398 and AZD4547. Synonyms: FIIN3; FIIN 3; FIIN-3. Grades: 98%. CAS No. 1637735-84-2. Molecular formula: C34H36Cl2N8O4. Mole weight: 691.61. | |
| Fisogatinib | Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC 50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BLU-554. CAS No. 1707289-21-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100492. | |
| FMK | FMK is a potent, highly specific and irreversible ribosomal s6 kinase (RSK) inhibitor that covalently modifies the C-terminal kinase domain of RSK. Its IC50 value is 15 nM. It could prevent the activation of the N-terminal kinase domain of RSK by the C-terminal kinase domain, but does not affect the activity of the N-terminal domain. It binds in the CTKD ATP-binding site and inhibits RSK autophosphorylation at Ser386. It induces significant apoptosis in human FGFR3-expressing, t(4;14)-positive multiple myeloma cells. It is used to determine the role of RSK as a direct regulator of NHE1 phosphorylation and sarcolemmal NHE activity in this cell type, in response to 1-adrenergic stimulation. Uses: Fmk could prevent the activation of the n-terminal kinase domain of rsk by the c-terminal kinase domain, but does not affect the activity of the n-terminal domain. it is used to determine the role of rsk as a direct regulator of nhe1 phosphorylation and sarcolemmal nhe activity in this cell type, in response to 1-adrenergic stimulation. Synonyms: 1-[4-Amino-7-(3-hydroxypropyl)-5-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-2-fluoroethanone;RSK2 kinase inhibitor. Grades: >98%. CAS No. 821794-92-7. Molecular formula: C18H19FN4O2. Mole weight: 342.37. | |
| Formononetin | Formononetin is a potent FGFR2 inhibitor with an IC 50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth [1]. Uses: Scientific research. Group: Natural products. Alternative Names: Biochanin B; Flavosil; Formononetol. CAS No. 485-72-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-N0183. | |
| Futibatinib | Futibatinib is an orally bioavailable, selective and irreversible inhibitor of fibroblast growth factor receptors (FGFRs), displaying antineoplastic activity. It inhibits FGFR-mediated signal transduction and tumor cell proliferation. Synonyms: 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1-pyrazolo[3,4-d]pyrimidinyl]-1-pyrrolidinyl]-2-propen-1-one; 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one. Grades: ≥ 98 %. CAS No. 1448169-71-8. Molecular formula: C22H22N6O3. Mole weight: 418.45. | |
Our database is helping our users find suppliers everyday.
